Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial

Area of Science:

• Oncology
• Genomics
• Metabolomics

Background:

• Breast cancer exhibits significant heterogeneity at genomic and metabolomic levels.
• This heterogeneity activates numerous signaling networks, leading to treatment resistance.
• Effective diagnosis and therapy are challenged by intra- and inter-tumor variability.

Purpose of the Study:

• To review breast cancer classification and therapeutic strategies.
• To examine model systems for personalized medicine approaches.
• To assess the efficacy of targeting cell signaling pathways in preclinical models.

Main Methods:

• Review of breast cancer subtypes: hormone-positive, HER2-positive, and triple-negative.
• Evaluation of preclinical breast cancer models.
• Testing a personalized medicine approach based on cell signaling pathway activation.

Main Results:

• A preclinical trial demonstrated effective and specific blockage of tumor growth.
• The approach was based solely on cell signaling pathway activation.
• Personalized medicine targeting signaling pathways shows promise.

Conclusions:

• Breast cancer heterogeneity necessitates advanced therapeutic strategies.
• Targeting cell signaling pathways offers a viable personalized medicine approach.
• Preclinical models are crucial for testing novel breast cancer therapies.